Gavilá, Joaquín <br/><br/>
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.  [electronic resource] 

 -  BMC medicine  01 2019 
 - 8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1741-7015 
<br/><br/><label>Standard No.: </label>10.1186/s12916-018-1233-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Cardiotoxicity--epidemiology<br/>Chemotherapy, Adjuvant--adverse effects<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoadjuvant Therapy--adverse effects<br/>Paclitaxel--administration & dosage<br/>Polyethylene Glycols--administration & dosage<br/>Receptor, ErbB-2<br/>Trastuzumab--administration & dosage